The A3 adenosine receptor agonist, namodenoson, ameliorates non‑alcoholic steatohepatitis in mice

Fishman,Pnina; Cohen,Shira; Itzhak,Inbal; Amer,Johnny; Salhab,Ahmad; Barer,Faina; Safadi,Rifaat

doi:10.3892/ijmm.2019.4364

The A3 adenosine receptor agonist, namodenoson, ameliorates non‑alcoholic steatohepatitis in mice

Authors:
- Pnina Fishman
- Shira Cohen
- Inbal Itzhak
- Johnny Amer
- Ahmad Salhab
- Faina Barer
- Rifaat Safadi
View Affiliations

Affiliations: Can‑Fite BioPharma Ltd., Petach‑Tikva 4951778, Israel, Liver Unit, Hadassah University Hospital, Jerusalem 54915, Israel
Published online on: October 3, 2019 https://doi.org/10.3892/ijmm.2019.4364
Pages: 2256-2264
Copyright: © Fishman et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The Wnt/β‑catenin pathway confers a chain of molecular events in livers affected by non‑alcoholic steatohepatitis (NASH). Namodenoson, a selective agonist of the A3 adenosine receptor (A3AR), which is highly expressed in pathological liver cells, induces a robust anti‑inflammatory effect in the liver, mediated via the de‑regulation of the Wnt/β‑catenin pathway. Namodenoson also acts as a liver protective agent by inhibiting ischemia/reperfusion injury. Based on these unique characteristics, we investigated the anti‑NASH effect of Namodenoson in murine models of steatohepatitis and in the LX2 human hepatic stellate cell line (HSC). In the STAM model, Namodenoson significantly decreased the non‑alcoholic fatty liver disease (NAFLD) activity score, NAS, demonstrating anti‑inflammatory and anti‑steatotic effects. In the carbon tetrachloride (CCl4) model, Namodenoson reversed alanine aminotransferase (ALT) to normal values and significantly improved liver inflammation and fibrosis, as well as the adiponectin and leptin levels. Namodenoson de‑regulated the Wnt/β‑catenin pathway in the liver extracts of the CCl4 model mice and in the LX2 HSCs, manifested by a decrease in the expression of phosphoinositide 3‑kinase (PI3K), nuclear factor κ‑light‑chain‑enhancer of activated B cells (NF‑κB), β‑catenin, lymphoid enhancer‑binding factor 1 (Lef‑1) and cyclin D1, and an increase in the expression level of glycogen synthase kinase 3β (GSK‑3β). The fibrosis marker, α‑smooth muscle actin (α‑SMA) was also de‑regulated, supporting the anti‑fibrotic effect of Namodenoson. On the whole, the findings of this study demonstrate that Namodenoson exerts an anti‑NASH effect mediated via the de‑regulation of the PI3K/NF‑κB/Wnt/β‑catenin signaling pathway. Thus, targeting A3AR may prove to be a novel direction in the pharmacotherapy of NAFLD/NASH.

View Figures

View References

1	Ratziu V, Bellentanib S, Cortez-Pintoc H, Dayd C and Marchesinie G: A position statement on NAFLD/NASH based on the EASL 2009, special conference. J Hepatol. 53:372–384. 2010. View Article : Google Scholar : PubMed/NCBI
2	Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL and Harrison SA: Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study. Gastroenterology. 140:124–131. 2011. View Article : Google Scholar
3	Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M and Sanyal AJ: The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastro-enterological association. Hepatology. 55:2005–2023. 2012. View Article : Google Scholar : PubMed/NCBI
4	Dhamija E, Paul SB and Kedia S: Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern. Indian J Med Res. 149:9–17. 2019. View Article : Google Scholar : PubMed/NCBI
5	Ratziu V, Goodman Z and Sanyal A: Current efforts and trends in the treatment of NASH. J Hepatol. 62(Suppl 1): S65–S75. 2015. View Article : Google Scholar : PubMed/NCBI
6	Takahashi Y, Sugimoto K, Inui H and Fukusato T: Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 21:3777–3785. 2015. View Article : Google Scholar : PubMed/NCBI
7	Guillaume M and Ratziu V: Pharmacological agents for nonalcoholic steatohepatitis. Hepatol Int. 7(Suppl 2): 833–841. 2013. View Article : Google Scholar : PubMed/NCBI
8	Cave MC, Clair HB, Hardesty JE, Falkner KC, Feng W, Clark BJ, Sidey J, Shi H, Aqel BA, McClain CJ and Prough RA: Nuclear receptors and nonalcoholic fatty liver disease. Biochim Biophys Acta. 1859:1083–1099. 2016. View Article : Google Scholar : PubMed/NCBI
9	Bar-Yehuda S, Stemmer SM, Madi L, Castel D, Ochaion A, Cohen S, Barer F, Zabutti A, Perez-Liz G, Del Valle L and Fishman P: The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. Int J Oncol. 33:287–295. 2008.PubMed/NCBI
10	Cohen S, Stemmer SM, Zozulya G, Ochaion A, Patoka R, Barer F, Bar-Yehuda S, Rath-Wolfson L, Jacobson KA and Fishman P: CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. J Cell Physiol. 226:2438–2447. 2011. View Article : Google Scholar : PubMed/NCBI
11	Ohana G, Cohen S, Rath-Wolfson L and Fishman P: A3 adenosine receptor agonist, CF102, protects against hepatic ischemia/reper-fusion injury following partial hepatectomy. Mol Med Rep. 14:4335–4341. 2016. View Article : Google Scholar : PubMed/NCBI
12	Stemmer SM, Benjaminov O, Medalia G, Ciuraru NB, Silverman MH, Bar-Yehuda S, Fishman S, Harpaz Z, Farbstein M, Cohen S, et al: CF102 for the treatment of hepatocellular carcinoma: A phase I/II, open-label, dose-escalation study. The Oncologist. 18:25–26. 2013. View Article : Google Scholar : PubMed/NCBI
13	Ochaion A, Bar-Yehuda S, Cohen S, Amital H, Jacobson KA, Joshi BV, Gao ZG, Barer F, Patoka R, Del Valle L, et al: The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats. Biochem Pharmacol. 76:482–494. 2008. View Article : Google Scholar : PubMed/NCBI
14	Fishman P, Bar-Yehuda S, Madi L, Rath-Wolfson L, Ochaion A, Cohen S and Baharav E: The PI3K-NF-κB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant induced arthritis. Arthritis Res Ther. 8:R332006. View Article : Google Scholar
15	Miao CG, Yang YY, He X, Huang C, Huang Y, Zhang L, Lv XW, Jin Y and Li J: Wnt signaling in liver fibrosis: Progress challenges and potential directions. Biochimie. 95:2326–2335. 2013. View Article : Google Scholar : PubMed/NCBI
16	Zhang C, Liu XQ, Sun HN, Meng XM, Bao YW, Zhang HP, Pan FM and Zhang C: Octreotide attenuates hepatic fibrosis and hepatic stellate cells proliferation and activation by inhibiting Wnt/β-catenin signaling pathway, c-Myc and cyclin D1. Int Immunopharmacol. 63:183–190. 2018. View Article : Google Scholar : PubMed/NCBI
17	Matsuda S, Kobayashi M and Kitagishi Y: Roles for PI3K/akt/PTEN pathway in cell signaling of nonalcoholic fatty liver disease. ISRN Endocrinol. 2013:4724322013. View Article : Google Scholar : PubMed/NCBI
18	Abu-Tair L, Axelrod JH, Doron S, Ovadya Y, Krizhanovsky V, Galun E, Amer J and Safadi R: Natural killer cell-dependent anti-fibrotic pathway in liver injury via toll-like receptor-9. PLoS One. 8:e825712013. View Article : Google Scholar : PubMed/NCBI
19	Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, et al: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41:1313–1321. 2005. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
21	Gomez G and Sitkovsky MV: Differential requirement for A2a and A3 adenosine receptors for the protective effect of inosine in vivo. Blood. 102:4472–4478. 2003. View Article : Google Scholar : PubMed/NCBI
22	Yoda-Murakami M, Taniguchi M, Takahashi K, Kawamata S, Saito K, Choi-Miura NH and Tomita M: Change in expression of GBP28/adiponectin in carbon tetrachloride-administrated mouse liver. Biochem Biophys Res Commun. 285:372–377. 2001. View Article : Google Scholar : PubMed/NCBI
23	Madi L, Bar-Yehuda S, Barer F, Ardon E, Ochaion A and Fishman P: A3 adenosine receptor activation in melanoma cells: Association between receptor fate and tumor growth inhibition. J Biol Chem. 278:42121–42130. 2003. View Article : Google Scholar : PubMed/NCBI
24	Ge WS, Wang YJ, Wu JX, Fan JG, Chen YW and Zhu L: β-catenin is overexpressed in hepatic fibrosis and blockage of Wnt/β-catenin signaling inhibits hepatic stellate cell activation. Mol Med Rep. 9:2145–2151. 2014. View Article : Google Scholar : PubMed/NCBI
25	Wang JN, Li L, Li LY, Yan Q, Li J and Xu T: Emerging role and therapeutic implication of Wnt signaling pathway in liver fibrosis. Gene. 674:57–69. 2018. View Article : Google Scholar : PubMed/NCBI
26	Núñez KG, Gonzalez-Rosario J, Thevenot PT and Cohen AJ: Cyclin D1 in the liver: Role of noncanonical signaling in liver steatosis and hormone regulation. Ochsner J. 17:56–65. 2017.PubMed/NCBI
27	Udomsinprasert W, Honsawek S and Poovorawan Y: Adiponectin as a novel biomarker for liver fibrosis. World J Hepatol. 10:708–718. 2018. View Article : Google Scholar : PubMed/NCBI
28	Chen GJ, Harvey BK, Shen H, Chou J, Victor A and Wang Y: Activation of adenosine A3 receptors reduces ischemic brain injury in rodents. J Neurosci Res. 84:1848–1855. 2006. View Article : Google Scholar : PubMed/NCBI
29	Cross HR, Murphy E, Black RG, Auchampach J and Steenbergen C: Overexpression of A(3) adenosine receptors decreases heart rate, preserves energetics, and protects ischemic hearts. Am J Physiol Heart Circ Physiol. 283:H1562–H1568. 2002. View Article : Google Scholar : PubMed/NCBI